Shannon Thyme Klinger net worth and biography

Shannon Klinger Biography and Net Worth

Insider of Moderna
A strategic, visionary leader, Ms. Klinger is driven by a deep personal and professional desire to meaningfully contribute to making the world a better place than she found it. As a breast cancer survivor, she has experienced first-hand the critical importance of creating sustainable health care systems capable of providing the right treatment for the right patient at the right time.

Ms. Klinger joined Moderna as chief legal officer on June 1, 2021. Most recently, she was chief legal officer at Novartis. Previously, she served as chief ethics, risk & compliance officer from April to May 2018, and was appointed to the Executive Committee of Novartis in this role. Before that, she was chief ethics and compliance officer and global head of litigation from 2016 to 2018. She joined Novartis in 2011 as general counsel for North America at Sandoz Inc., and later served as general counsel and global head of legal at Sandoz International from 2012 to 2016. Prior to Novartis, Ms. Klinger was a partner at Mayer Brown from 2010 to 2011, and general counsel and senior vice president at Solvay Pharmaceuticals from 2008 to 2010.

Ms. Klinger holds a juris doctor with honors from The University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the University of Notre Dame. She is a member of the State Bar of Georgia and of the District of Columbia Bar.

What is Shannon Thyme Klinger's net worth?

The estimated net worth of Shannon Thyme Klinger is at least $684,164.25 as of September 8th, 2022. Ms. Klinger owns 3,949 shares of Moderna stock worth more than $684,164 as of February 5th. This net worth estimate does not reflect any other investments that Ms. Klinger may own. Learn More about Shannon Thyme Klinger's net worth.

How do I contact Shannon Thyme Klinger?

The corporate mailing address for Ms. Klinger and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected] Learn More on Shannon Thyme Klinger's contact information.

Has Shannon Thyme Klinger been buying or selling shares of Moderna?

Shannon Thyme Klinger has not been actively trading shares of Moderna in the last ninety days. Most recently, Shannon Thyme Klinger sold 478 shares of the business's stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $137.44, for a transaction totalling $65,696.32. Following the completion of the sale, the insider now directly owns 3,949 shares of the company's stock, valued at $542,750.56. Learn More on Shannon Thyme Klinger's trading history.

Who are Moderna's active insiders?

Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.

Are insiders buying or selling shares of Moderna?

During the last year, insiders at the sold shares 129 times. They sold a total of 1,870,030 shares worth more than $292,327,157.37. The most recent insider tranaction occured on January, 26th when CEO Stephane Bancel sold 40,000 shares worth more than $7,626,800.00. Insiders at Moderna own 17.3% of the company. Learn More about insider trades at Moderna.

Information on this page was last updated on 1/26/2023.

Shannon Thyme Klinger Insider Trading History at Moderna

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/8/2022Sell478$137.44$65,696.323,949View SEC Filing Icon  
6/8/2022Sell1,265$148.12$187,371.803,289View SEC Filing Icon  
See Full Table

Shannon Thyme Klinger Buying and Selling Activity at Moderna

This chart shows Shannon Thyme Klinger's buying and selling at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moderna Company Overview

Moderna logo
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $173.25
Low: $172.40
High: $178.74

50 Day Range

MA: $186.36
Low: $165.13
High: $210.04

2 Week Range

Now: $173.25
Low: $115.03
High: $217.25

Volume

2,821,351 shs

Average Volume

3,780,459 shs

Market Capitalization

$66.56 billion

P/E Ratio

6.27

Dividend Yield

N/A

Beta

1.65